$DEPO (DepoMed Inc.)

$DEPO {{ '2016-05-18T22:06:03+0000' | timeago}} • Announcement

$DEPO said the U.S. District Court of New Jersey judge entered order enjoining any of Actavis Elizabeth, Actavis, Alkem, Ascend Laboratories, Roxane and Watson Laboratories from marketing generic versions of any of NUCYNTA, NUCYNTA ER or NUCYNTA oral solution prior to the Court's issuance of a decision in the pending patent litigation.

$VRTX {{ '2017-07-25T21:51:58+0000' | timeago}} • Announcement

$VRTX and $CNCE completed an asset purchase agreement, under which $VRTX gained worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. $CNCE received $160MM in cash upon closing and is eligible to receive up to $90MM in additional milestones.

$LLY {{ '2017-07-25T14:13:17+0000' | timeago}} • Announcement

$LLY, which joined hands with $NKTR recently to co-develop the autoimmune drug NKTR-358, cut down its GAAP earnings outlook for FY17 by $0.09 per share to $2.51-2.61. However, Eli Lilly lifted its non-GAAP EPS estimate to $4.10-4.20 from the prior outlook of $4.05-4.15 Revenue outlook also lifted to $22.0-22.5Bil from prior range of $21.8-22.3Bil.

$LLY {{ '2017-07-24T18:19:30+0000' | timeago}} • Announcement

$LLY to co-develop $NKTR's autoimmune drug NKTR-358. Under the deal terms, Eli Lilly will pay Nektar Therapeutics an upfront payment of $150MM and up to $250MM if development and regulatory milestones are achieved. Nektar to complete Phase 1 clinical development and will bear 25% of Phase 2 cost. $LLY will bear 75% of the Phase 2 development cost.

$ENDP {{ '2017-07-21T14:56:21+0000' | timeago}} • Announcement

$ENDP said it will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure is expected to take place over the next 12 to 18 months. These restructuring actions are expected to reduce $ENDP's workforce by about 875 positions and to result in pre-tax restructuring charges of about $325MM.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$NKTR {{ '2017-07-18T13:13:43+0000' | timeago}} • Announcement

Pharma company $NKTR said a study on pain relief drug NKTR-181 demonstrated less abuse potential, compared to commonly used medicine oxycodone.  The study was designed to assess the relative oral abuse potential of the formulation at its maximum dose. The FDA has granted NKTR-181 fast track designation for treatment of moderate to severe pain.

$DEPO {{ '2017-07-13T12:48:44+0000' | timeago}} • Announcement

Pharma company $DEPO is seeking to refinance its existing $375MM principal amount of privately placed secured senior notes. The notes are due in 2022. The terms of refinancing are subject to various factors, including satisfaction of customary closing conditions.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$ENDP {{ '2017-07-06T17:01:40+0000' | timeago}} • Announcement

Following FDA's June 2017 withdrawal request, $ENDP has decided to voluntarily remove OPANA ER, a painkiller, from the market, to prevent its misuse.  As a result, $ENDP expects to incur a pre-tax impairment charge of approx $20MM in 2Q17. Reported net sales of OPANA ER were $158.9MM for FY16 and $35.7MM for 1Q17.

$ENDP {{ '2017-07-05T12:36:12+0000' | timeago}} • Announcement

$ENDP today announced it has entered into a definitive agreement to sell Mexico City-based Grupo Farmacéutico SOMAR to Advent International for approximately $124MM subject to customary adjustments for cash, debt and working capital.

$ENDP {{ '2017-07-03T18:36:53+0000' | timeago}} • Announcement

$ENDP completed the divestiture of its South African based operations, Litha Healthcare Group, to Acino Pharma AG. At closing, the company received approx. $100MM in cash and may receive up to an additional $11MM in contingent consideration.

$ACOR {{ '2017-06-29T20:59:19+0000' | timeago}} • Announcement

$ACOR submits New Drug Application (NDA) to FDA for Inbrija, a potential therapy for patients with Parkinson’s disease. Acorda Therapeutics plans to file a Marketing Authorization Application (MAA) in Europe for Inbrija by the end of 2017.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

$AMGN {{ '2017-06-07T14:18:46+0000' | timeago}} • Announcement

$AMGN and $AGN said that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab), on July 13, 2017. Bevacizumab is medication used to treat types of cancers and specific eye disease.

$AGN {{ '2017-06-07T14:08:57+0000' | timeago}} • Announcement

$AGN's subsidiary Allergan Sales LLC agreed to buy privately-held Keller Medical, a medical device company and developer of the Keller Funnel. The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during breast augmentation or reconstruction procedures.

$ACOR {{ '2017-06-06T13:47:37+0000' | timeago}} • Announcement

$ACOR presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically significant, clinically meaningful improvement in motor function, as measured by the Unified Parkinson's Disease Rating Scale - Part III (UPDRS III) in people with Parkinson's experiencing OFF periods.

$NKTR {{ '2017-06-05T13:23:39+0000' | timeago}} • Announcement

$NKTR presented new clinical data from two studies of NKTR-214, a CD122-biased agonist, its lead immuno-oncology candidate at the 2017 American Society of Clinical Oncology Annual Meeting. This is designed to expand specific cancer-fighting CD8 effector T cells and natural killer cells directly in tumor micro-environment.

$AGN {{ '2017-05-24T14:41:46+0000' | timeago}} • Announcement

$AGN announced the early tender results for tender offers commenced by its subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, and Allergan Inc., each as co-offeror with $AGN's subsidiary Warner Chilcott Ltd., to purchase for cash certain debt securities issued by the entities.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
NKTR (Nektar Therapeutics)
Tuesday, May 9 2017 - 9:00pm
DEPO (DepoMed Inc.)
Tuesday, May 9 2017 - 8:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, May 9 2017 - 3:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, May 8 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
INSM (Insmed Incorporated)
Wednesday, May 3 2017 - 12:30pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, April 27 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, March 14 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, March 14 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
NKTR (Nektar Therapeutics)
Wednesday, March 1 2017 - 10:00pm

AlphaGraphics you may like